
Itziar Casado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/899395/publications.pdf Version: 2024-02-01



ITZIAD CASADO

#	Article	IF	CITATIONS
1	Transmission of SARS-CoV-2 infection and risk factors in a cohort of close contacts. Postgraduate Medicine, 2022, 134, 230-238.	2.0	14
2	Chronic obstructive pulmonary disease and influenza vaccination effect in preventing outpatient and inpatient influenza cases. Scientific Reports, 2022, 12, 4862.	3.3	5
3	Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Microbiology Spectrum, 2022, 10, e0000822.	3.0	17
4	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Eurosurveillance, 2022, 27, .	7.0	16
5	Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22. Eurosurveillance, 2022, 27, .	7.0	6
6	Independent Role of Severe Obesity as a Risk Factor for COVIDâ€19 Hospitalization: A Spanish Populationâ€Based Cohort Study. Obesity, 2021, 29, 29-37.	3.0	46
7	Absence of association between 2019â€20 influenza vaccination and COVIDâ€19: Results of the European lâ€MOVEâ€COVIDâ€19 primary care project, Marchâ€August 2020. Influenza and Other Respiratory Viruses, 202 15, 429-438.	13.4	21
8	Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Eurosurveillance, 2021, 26, .	7.0	55
9	Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 2608.	2.4	42
10	Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Eurosurveillance, 2021, 26, .	7.0	38
11	Effect of influenza vaccination in patients with asthma. Cmaj, 2021, 193, E1120-E1128.	2.0	7
12	Simple models to include influenza vaccination history when evaluating the effect of influenza vaccination. Eurosurveillance, 2021, 26, .	7.0	4
13	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Eurosurveillance, 2021, 26, .	7.0	48
14	Effect of Influenza Vaccination in Preventing Laboratory-Confirmed Influenza Hospitalization in Patients With Diabetes Mellitus. Clinical Infectious Diseases, 2020, 73, 107-114.	5.8	18
15	Vaccine effectiveness against influenza A(H3N2) and B among laboratoryâ€confirmed, hospitalised older adults, Europe, 2017â€l 8: A season of B lineage mismatched to the trivalent vaccine. Influenza and Other Respiratory Viruses, 2020, 14, 302-310.	3.4	15
16	Effectiveness of the current and prior influenza vaccinations in Northern Spain, 2018–2019. Vaccine, 2020, 38, 1925-1932.	3.8	9
17	Remaining Effect of Influenza Vaccines Received in Prior Seasons. Journal of Infectious Diseases, 2019, 220, 1136-1140.	4.0	12
18	Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. Expert Review of Gastroenterology and Hepatology, 2019, 13, 699-708.	3.0	9

ITZIAR CASADO

#	Article	IF	CITATIONS
19	La enfermedad por virus Zika en España. Resultados de la vigilancia y epidemiologÃa de los casos notificados en 2015-2017. Medicina ClÃnica, 2019, 153, 6-12.	0.6	4
20	Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case–control study. Cmaj, 2018, 190, E3-E12.	2.0	40
21	Estimación de la prevalencia de infección diagnosticada y no diagnosticada por el virus de la hepatitis C en Navarra, 2014-2016. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 325-331.	0.5	22
22	Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS ONE, 2018, 13, e0208554.	2.5	16
23	Detection of Respiratory Viruses in Deceased Persons, Spain, 2017. Emerging Infectious Diseases, 2018, 24, 1331-1334.	4.3	7
24	Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. Revista Espanola De Enfermedades Digestivas, 2018, 110, 621-628.	0.3	11
25	Comparison of influenza vaccine effectiveness in preventing outpatient and inpatient influenza cases in older adults, northern Spain, 2010/11 to 2015/16. Eurosurveillance, 2018, 23, .	7.0	16
26	Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. Eurosurveillance, 2018, 23, .	7.0	27
27	Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus. Journal of Infectious Diseases, 2017, 215, 847-855.	4.0	35
28	2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Eurosurveillance, 2017, 22, .	7.0	29
29	Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. Eurosurveillance, 2017, 22, .	7.0	29
30	Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis. Eurosurveillance, 2017, 22, .	7.0	24
31	Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Review of Vaccines, 2016, 15, 425-432.	4.4	41
32	Effectiveness of subunit influenza vaccination in the 2014–2015 season and residual effect of split vaccination in previous seasons. Vaccine, 2016, 34, 1350-1357.	3.8	32
33	Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season. Eurosurveillance, 2016, 21, .	7.0	20
34	Temporal evolution of brain cancer incidence in the municipalities of Navarre and the Basque Country, Spain. BMC Public Health, 2015, 15, 1018.	2.9	8
35	Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. Human Vaccines and Immunotherapeutics, 2015, 11, 1626-1633.	3.3	20
36	Household Transmission of Influenza A(H1N1)pdm09 in the Pandemic and Post-Pandemic Seasons. PLoS ONE, 2014, 9, e108485.	2.5	15

#	Article	IF	CITATIONS
37	Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class. Clinical Microbiology and Infection, 2012, 18, E485-E490.	6.0	26